STEREOSELECTIVE HYDROXYLATION OF MEXILETINE IN HUMAN LIVER-MICROSOMES - IMPLICATION OF P450IID6 - A PRELIMINARY-REPORT

被引:31
作者
VANDAMME, N
BROLY, F
LIBERSA, C
COURSEAU, C
LHERMITTE, M
机构
[1] CTR HOSP REG & UNIV LILLE,HOP CALMETTE,BIOCHIM LAB,TOXICOL SECT,BD PR J LECLERCQ,F-59037 LILLE,FRANCE
[2] FAC MED LILLE,PHARMACOL LAB,F-59045 LILLE,FRANCE
[3] UNIV LILLE 2,TOXICOL LAB,F-59800 LILLE,FRANCE
[4] LABS BOEHRINGER INGELHEIM FRANCE,REIMS,FRANCE
关键词
MEXILETINE; ENANTIOMER; P450IID6; HYDROXYLATION; HUMAN LIVER;
D O I
10.1097/00005344-199301000-00011
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Mexiletine, a class Ib antiarrythmic drug, is used clinically as a racemic mixture of two enantiomers. Aromatic and aliphatic hydroxylation are the two major metabolic steps. In the liver, this metabolism is catalyzed by the cytochrome P450IID6, an isoenzyme of cytochrome P450 due to genetic polymorphism in humans. In the present study, the metabolism of the two stereoisomers was compared in vitro in human liver microsomes. Parahydroxylation (aromatic hydroxylation) is favored for S(+)-mexiletine with a mean intrinsic clearance higher than for R(-)-mexiletine. The R(-) enantiomer exhibits a threefold higher mean V(max) value for aliphatic hydroxylation than S(+)-mexiletine. We showed that (i) the high-affinity component of dextrometorphan 0-demethylation was competitively inhibited by R(-)- and S(+)-mexiletine and that (ii) hydroxylations of the two enantiomers were very strongly competitively inhibited by quinidine. Hydroxylation reactions of mexiletine exhibit stereoselectivity in vitro in human liver microsomes and are catalyzed by P450IID6.
引用
收藏
页码:77 / 83
页数:7
相关论文
共 27 条
[1]   CLINICAL CONSEQUENCES OF POLYMORPHIC DRUG OXIDATION [J].
ALVAN, G .
FUNDAMENTAL & CLINICAL PHARMACOLOGY, 1991, 5 (03) :209-228
[2]  
BECKETT AH, 1977, POSTGRAD MED J, V53, P60
[3]  
BROLY F, 1990, DRUG METAB DISPOS, V18, P362
[4]   EFFECT OF QUINIDINE ON THE DEXTROMETHORPHAN O-DEMETHYLASE ACTIVITY OF MICROSOMAL FRACTIONS FROM HUMAN-LIVER [J].
BROLY, F ;
LIBERSA, C ;
LHERMITTE, M ;
BECHTEL, P ;
DUPUIS, B .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1989, 28 (01) :29-36
[5]   DEBRISOQUINE SPARTEINE HYDROXYLATION GENOTYPE AND PHENOTYPE - ANALYSIS OF COMMON MUTATIONS AND ALLELES OF CYP2D6 IN A EUROPEAN POPULATION [J].
BROLY, F ;
GAEDIGK, A ;
HEIM, M ;
EICHELBAUM, M ;
MORIKE, K ;
MEYER, UA .
DNA AND CELL BIOLOGY, 1991, 10 (08) :545-558
[6]   INHIBITORY STUDIES OF MEXILETINE AND DEXTROMETHORPHAN OXIDATION IN HUMAN LIVER-MICROSOMES [J].
BROLY, F ;
LIBERSA, C ;
LHERMITTE, M ;
DUPUIS, B .
BIOCHEMICAL PHARMACOLOGY, 1990, 39 (06) :1045-1053
[7]   THE METABOLISM OF MEXILETINE IN RELATION TO THE DEBRISOQUINE SPARTEINE-TYPE POLYMORPHISM OF DRUG OXIDATION [J].
BROLY, F ;
VANDAMME, N ;
LIBERSA, C ;
LHERMITTE, M .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1991, 32 (04) :459-466
[8]  
BROLY F, 1992, PHARMACOCINETIQUE RE, P421
[9]  
CAMPBELL NPS, 1978, BRIT J CLIN PHARMACO, V6, P103, DOI 10.1111/j.1365-2125.1978.tb00833.x